Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$70.57 USD

70.57
88,152

+0.20 (0.28%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $70.64 +0.07 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

by Zacks Equity Research

Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.

BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.

Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

by Zacks Equity Research

Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

by Zacks Equity Research

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

by Zacks Equity Research

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

by Zacks Equity Research

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

by Zacks Equity Research

Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.

Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why

by Zacks Equity Research

Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

by Zacks Equity Research

Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.

Corcept (CORT) Completes Enrollment in Phase II ALS Study

by Zacks Equity Research

The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

by Zacks Equity Research

The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

by Zacks Equity Research

Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors

by Zacks Equity Research

Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.

AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

by Zacks Equity Research

The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.

Vincerx (VINC) Tumbles on Results From Cancer Therapy Study

by Zacks Equity Research

Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.

Corcept (CORT) Completes Enrollment in Ovarian Cancer Study

by Zacks Equity Research

The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.

Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study

by Zacks Equity Research

A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.

Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why

by Zacks Equity Research

Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why

by Zacks Equity Research

MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.

Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed at $77.96 in the latest trading session, marking a -0.03% move from the prior day.

AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase III ADRIATIC study.

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

by Zacks Equity Research

Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.